OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia

Hiroyuki Kiriyama; Junichi Ishida; Hiroshi Kadowaki; Takeshi Iwasa; Arihiro Kiyosue; Satoshi Kodera; Jiro Ando; Hiroshi Akazawa; Issei Komuro

doi:10.1016/j.jaccao.2019.09.006

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia

JACC CardioOncol. 2019 Dec 17;1(2):318-321. doi: 10.1016/j.jaccao.2019.09.006. eCollection 2019 Dec.

Authors

Hiroyuki Kiriyama¹, Junichi Ishida¹, Hiroshi Kadowaki¹, Takeshi Iwasa², Arihiro Kiyosue¹, Satoshi Kodera¹, Jiro Ando¹, Hiroshi Akazawa¹, Issei Komuro¹

Affiliations

¹ Department of Cardiovascular Medicine, University of Tokyo Hospital, Tokyo, Japan.
² Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.

No abstract available

Keywords: CAD, coronary artery disease; CML, chronic myeloid leukemia; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; IVUS, intravascular ultrasound; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; TKI, tyrosine kinase inhibitor; bcr-abl tyrosine kinase inhibitor; coronary artery disease; leukemia; nilotinib; optical coherence tomography; percutaneous coronary intervention; thrombosis.

Publication types

Review